EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

PI3K signaling in breast cancer: therapeutic advances versus adaptive resistance

Fabiana Napolitano, Nisha Unni, Carlos L Arteaga

Journal of Clinical Investigation · 2026

DOI: 10.1172/jci207635 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Clinical Investigation, 2026. Verfasst von Fabiana Napolitano und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy. Hauptthemen laut MEDLINE: Breast Neoplasms, Signal Transduction, Drug Resistance, Neoplasm, Phosphatidylinositol 3-Kinases. Die Arbeit nennt 124 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Somatic alterations in the phosphoinositide 3-kinase (PI3K) pathway are frequent oncogenic drivers in cancer and are particularly relevant in estrogen receptor–positive breast cancer, where PI3K signaling integrates hormonal, growth factor, and metabolic inputs. Therapeutic targeting of PI3K has been limited by toxicity, pathway crosstalk, and adaptive resistance. Recent advances in structural and functional characterization of PIK3CA mutations have enabled the development of more selective inhibitors, including PI3K isoform–selective and emerging allosteric PI3Ka mutant–targeted compounds. These approaches aim to improve the therapeutic index while maintaining pathway inhibition. In parallel, combination strategies with endocrine therapy and CDK4/6 inhibitors have demonstrated clinical benefit in selected patient populations. However, responses are often transient owing to compensatory signaling and pathway reactivation. Additional metabolic and transcriptional adaptations further contribute to sustaining tumor cell survival. Overall, PI3K-targeted therapy is evolving along two complementary paths: increased mutant-selective inhibition to improve therapeutic index and broader pathway-level strategies designed to overcome adaptive resistance and achieve more durable responses. Ongoing efforts focus on optimizing combination strategies, enhancing development of predictive biomarkers, and improving therapeutic sequencing to achieve durable responses while minimizing toxicity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsSignal TransductionDrug Resistance, NeoplasmPhosphatidylinositol 3-KinasesPhosphoinositide-3 Kinase InhibitorsNeoplasm ProteinsHumansFemaleAnimalsClass I Phosphatidylinositol 3-KinasesMutation

Substanzen

Phosphatidylinositol 3-KinasesPhosphoinositide-3 Kinase InhibitorsPIK3CA protein, humanClass I Phosphatidylinositol 3-KinasesNeoplasm Proteins

Autor:innen und Institutionen

  • Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
  • UT Southwestern Simmons Comprehensive Cancer Center and.
  • Department of Internal Medicine, UT Southwestern Medical Center, Dallas, Texas, USA.

Zitieren

APA

Napolitano, F., Unni, N., & Arteaga, C. L. (2026). PI3K signaling in breast cancer: therapeutic advances versus adaptive resistance. Journal of Clinical Investigation. https://doi.org/10.1172/jci207635

Vancouver

Napolitano F, Unni N, Arteaga CL. PI3K signaling in breast cancer: therapeutic advances versus adaptive resistance. Journal of Clinical Investigation. 2026. doi:10.1172/jci207635

BibTeX
@article{Napolitano2026,
  author = {Napolitano, Fabiana and Unni, Nisha and Arteaga, Carlos L},
  title = {PI3K signaling in breast cancer: therapeutic advances versus adaptive resistance},
  journal = {Journal of Clinical Investigation},
  year = {2026},
  doi = {10.1172/jci207635}
}
Kostenlos starten →